(ADCT) ADC Therapeutics - Ratings and Ratios
Zynlonta, CD19-ADC, CD22-ADC, ADCT-602
ADCT EPS (Earnings per Share)
ADCT Revenue
Description: ADCT ADC Therapeutics October 28, 2025
ADC Therapeutics SA (NYSE:ADCT) commercializes an antibody-drug conjugate (ADC) platform focused on hematologic malignancies and solid tumors. Its lead asset, ZYNLONTA (loncastuximab tesirine), is a CD19-directed ADC that has secured accelerated FDA approval, conditional European Commission approval, and conditional China NMPA approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after ≥ 2 prior lines of therapy.
The company is pursuing geographic and line-of-therapy expansion of ZYNLONTA through the LOTIS-5 confirmatory Phase 3 trial (earlier-line DLBCL) and LOTIS-7 Phase 1b trial (follicular lymphoma, marginal zone lymphoma, and combination regimens). Additional clinical activity includes a CD-22-targeted ADC and ADCT-602 in a Phase 1/2 investigator-initiated trial for refractory B-cell acute lymphoblastic leukemia, plus a pre-clinical pipeline of next-generation ADCs against Claudin-6, NaPi2b, PSMA, and ASCT2.
From a market-size perspective, the global ADC market is projected to grow at a ~13 % CAGR through 2030, driven by rising oncology spending, favorable reimbursement trends, and increasing FDA approvals of ADCs. ADCT reported ~CHF 150 million of cash and cash equivalents at year-end 2023, giving it runway into 2025 under current burn rates. However, revenue visibility hinges on successful Phase 3 readouts, commercial launch execution, and the company’s ability to secure reimbursement in major markets-each of which carries material uncertainty.
For a deeper, data-driven assessment of ADCT’s valuation and risk profile, you may find the analyst toolkit on ValueRay worth exploring.
ADCT Stock Overview
| Market Cap in USD | 458m |
| Sub-Industry | Communications Equipment |
| IPO / Inception | 1979-03-16 |
ADCT Stock Ratings
| Growth Rating | 11.2% |
| Fundamental | 54.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 14.0% |
| Analyst Rating | 4.67 of 5 |
ADCT Dividends
Currently no dividends paidADCT Growth Ratios
| Growth Correlation 3m | 92.9% |
| Growth Correlation 12m | 61.9% |
| Growth Correlation 5y | -77.1% |
| CAGR 5y | -0.64% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.01 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.01 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | 7.47 |
| Beta | 1.995 |
| Volatility | 92.40% |
| Current Volume | 920.3k |
| Average Volume 20d | 920.3k |
| Stop Loss | 3.8 (-9.1%) |
| Signal | -0.40 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-169.9m TTM) > 0 and > 6% of Revenue (6% = 4.63m TTM) |
| FCFTA -0.40 (>2.0%) and ΔFCFTA -0.95pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 329.0% (prev 446.1%; Δ -117.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.40 (>3.0%) and CFO -127.3m > Net Income -169.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (113.7m) change vs 12m ago 18.86% (target <= -2.0% for YES) |
| Gross Margin 93.37% (prev 89.53%; Δ 3.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 22.28% (prev 17.95%; Δ 4.33pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.42 (EBITDA TTM -118.6m / Interest Expense TTM 50.3m) >= 6 (WARN >= 3) |
Altman Z'' -16.47
| (A) 0.79 = (Total Current Assets 318.8m - Total Current Liabilities 64.6m) / Total Assets 321.6m |
| (B) -4.94 = Retained Earnings (Balance) -1.59b / Total Assets 321.6m |
| warn (B) unusual magnitude: -4.94 — check mapping/units |
| (C) -0.35 = EBIT TTM -121.8m / Avg Total Assets 346.7m |
| (D) -3.03 = Book Value of Equity -1.58b / Total Liabilities 520.7m |
| Total Rating: -16.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 54.15
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -41.14% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity -0.59 = -2.50 |
| 5. Debt/Ebitda 1.24 = 1.40 |
| 6. ROIC - WACC (= 127.0)% = 12.50 |
| 7. RoE 83.72% = 2.50 |
| 8. Rev. Trend -58.71% = -4.40 |
| 9. EPS Trend 62.99% = 3.15 |
What is the price of ADCT shares?
Over the past week, the price has changed by -2.56%, over one month by +2.45%, over three months by +53.11% and over the past year by +38.41%.
Is ADC Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ADCT is around 4.18 USD . This means that ADCT is currently overvalued and has a potential downside of 0%.
Is ADCT a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ADCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8 | 91.4% |
| Analysts Target Price | 8 | 91.4% |
| ValueRay Target Price | 4.8 | 15.8% |
ADCT Fundamental Data Overview October 25, 2025
P/S = 5.9275
P/B = 2.5787
Beta = 1.995
Revenue TTM = 77.2m USD
EBIT TTM = -121.8m USD
EBITDA TTM = -118.6m USD
Long Term Debt = 114.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.79m USD (from shortTermDebt, last quarter)
Debt = 117.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -147.0m USD (from netDebt column, last quarter)
Enterprise Value = 310.8m USD (457.9m + Debt 117.5m - CCE 264.6m)
Interest Coverage Ratio = -2.42 (Ebit TTM -121.8m / Interest Expense TTM 50.3m)
FCF Yield = -41.14% (FCF TTM -127.9m / Enterprise Value 310.8m)
FCF Margin = -165.6% (FCF TTM -127.9m / Revenue TTM 77.2m)
Net Margin = -220.0% (Net Income TTM -169.9m / Revenue TTM 77.2m)
Gross Margin = 93.37% ((Revenue TTM 77.2m - Cost of Revenue TTM 5.12m) / Revenue TTM)
Gross Margin QoQ = 95.56% (prev 91.05%)
Tobins Q-Ratio = 0.97 (Enterprise Value 310.8m / Total Assets 321.6m)
Interest Expense / Debt = 11.06% (Interest Expense 13.0m / Debt 117.5m)
Taxrate = -2.26% (negative due to tax credits) (1.25m / -55.4m)
NOPAT = -124.5m (EBIT -121.8m * (1 - -2.26%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.93 (Total Current Assets 318.8m / Total Current Liabilities 64.6m)
Debt / Equity = -0.59 (negative equity) (Debt 117.5m / totalStockholderEquity, last quarter -199.2m)
Debt / EBITDA = 1.24 (negative EBITDA) (Net Debt -147.0m / EBITDA -118.6m)
Debt / FCF = 1.15 (negative FCF - burning cash) (Net Debt -147.0m / FCF TTM -127.9m)
Total Stockholder Equity = -203.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.85% (Net Income -169.9m / Total Assets 321.6m)
RoE = 83.72% (negative equity) (Net Income TTM -169.9m / Total Stockholder Equity -203.0m)
RoCE = 137.6% (negative capital employed) (EBIT -121.8m / Capital Employed (Equity -203.0m + L.T.Debt 114.5m))
RoIC = 140.0% (negative operating profit) (NOPAT -124.5m / Invested Capital -89.0m)
WACC = 12.95% (E(457.9m)/V(575.4m) * Re(13.37%) + D(117.5m)/V(575.4m) * Rd(11.06%) * (1-Tc(-0.02)))
Discount Rate = 13.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.57%
Fair Price DCF = unknown (Cash Flow -127.9m)
EPS Correlation: 62.99 | EPS CAGR: 12.71% | SUE: 1.64 | # QB: 1
Revenue Correlation: -58.71 | Revenue CAGR: -39.87% | SUE: 0.12 | # QB: 0
Additional Sources for ADCT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle